What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
about
Acute lymphoblastic leukaemiaL-asparaginase in the treatment of patients with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseAntigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomabMonoclonal antibodies in acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHow I treat acute lymphoblastic leukemia in older adolescents and young adultsChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationPegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trialDelays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.Treatment of adolescent and young adults with acute lymphoblastic leukemiaBlood consult: therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemiaClinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?Declining childhood and adolescent cancer mortalityAllogeneic hematopoietic cell transplantation: the state of the artRationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.Use of appropriate initial treatment among adolescents and young adults with cancer.Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults ProtocolsYoung adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Comparison of survival at adult versus pediatric treatment centers for rare pediatric tumors in an adolescent and young adult (AYA) population in the State of GeorgiaClinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survivalImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.Who Treats Adolescents and Young Adults with Cancer? A Report from the AYA HOPE Study.
P2860
Q24602387-75FC1E59-3DEA-4004-93BD-766950A975D9Q26738640-F1942E92-DFF4-4821-AECE-BA18744CCC02Q26784116-BA80D4AA-96BF-4147-8F5C-3291B5BD967AQ27013710-7B1C4D2C-5312-4F34-8861-45224D587AD5Q27022540-3C95B7A4-35F5-4079-AFE9-D99E65D6AE4EQ27026476-CF5AECDC-1DE0-4696-86AB-7C3FB9DC8C8FQ28087589-043DCE10-CACF-473D-8AB7-47E5DC2F6463Q28087637-9457FDCB-2199-40A6-89B1-D153B864796BQ31118945-FA681D75-19B3-4232-A4FF-290561DBA46CQ33434223-15361A70-B7F0-44EA-B4A9-21822DDDF156Q33583302-D0DEC0AA-12B0-4032-A98F-9E9D82B69A85Q33605181-64C4211F-2709-4883-A4A8-57CE64F9155FQ33711119-AE886373-1678-4856-ABD8-482B47D39C52Q33747668-6B535EB6-6D1B-40DF-BCA4-F7AB98BC3B6AQ33865329-B39CFD1A-BA23-4F3A-8C87-6A74840852B3Q33897659-4FE9762A-6368-48B3-A4CD-8C75E8ADC774Q33920153-76EA23D9-2D08-48BA-AD49-E90EB874B478Q34009088-FC3CFE19-AB8F-4F07-A2D2-CD0938A630A5Q34028600-3DFD0913-001B-4820-BF71-44E797A928BEQ34060045-2930C901-BA6C-4FB3-927E-2A6D8295E05BQ34145155-389F9D3D-D508-4854-9591-F6FFFD8A64A4Q34325815-CE7B7323-B0B0-4532-B600-2A95E6F7701EQ34354175-B55EEB6C-152C-4CEC-9AAC-72013C5EB3DBQ34454611-3BFEA030-DD1A-421B-B273-4C0F89AD5BC2Q34455093-81A22BD3-C49A-4009-9E33-27EF94C8B989Q34550540-7CED7EA6-0B2D-4731-A80B-2BB47655263AQ34610024-7654063C-FCA1-4BF8-B38B-392A62BC1F4FQ34645985-188D6FFE-5209-4C7F-9158-A6B03AAF3BEFQ34679298-A57B5211-E4EE-42CB-ABE8-757DB381D7E3Q34764504-3DD2CCCF-3DC1-4D41-81A9-C7C3F82B22F5Q34820332-0D29C733-B659-4215-9ABE-8510A4367B09Q35004970-43E2972D-7E42-453B-A8EB-EFE0C1DE9399Q35008064-ACAFCD43-A4F2-4B65-ADB2-57EF2CF3ECA6Q35021459-2C2C9FF1-2298-4915-B4CD-5CB03241CCA6Q35178966-BE7C6CC8-D737-453E-954E-0C0656866717Q35437903-5EE4F538-2D1D-4FF5-B776-B8F07460034AQ35691002-8FDAE315-DA6A-46ED-A766-716706E34816Q35901969-F78BDC6A-2383-4EE6-9E5E-60B328F2D456Q36058255-80C285BC-90CC-4FFB-942C-234533C22BD8Q36074130-11C25555-FDF4-4DC2-B9EB-7D591C2C82DE
P2860
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
What determines the outcomes f ...... r and Leukemia Group B studies
@en
type
label
What determines the outcomes f ...... r and Leukemia Group B studies
@en
prefLabel
What determines the outcomes f ...... r and Leukemia Group B studies
@en
P2093
P2860
P1433
P1476
What determines the outcomes f ...... r and Leukemia Group B studies
@en
P2093
Ben Sanford
Cancer and Leukemia Group B studies
Children's Cancer Group
James Nachman
James W Vardiman
Richard A Larson
Wendy Stock
P2860
P304
P356
10.1182/BLOOD-2008-01-130237
P407
P577
2008-05-23T00:00:00Z